InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director
InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors. In addition to his board responsibilities, Dr. Levick will provide scientific and clinical development guidance to the board and management as the company advances its pipeline towards clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries. Mark’s expertise was gained through a 25+ year international career leading global research and development groups as Global Head of Development at Sandoz Biopharmaceuticals; Senior Vice President, Global Drug Discovery at Novartis; and Vice-President, Biopharmaceutical Translational Medicine at GSK. Mark oversaw R&D programs that resulted in thirteen drug approvals, including five first-in-class molecules and two approvals arising from successful human proof-of-concept programs. Before joining the industry, Mark was a medical reviewer for the UK and EU medicines regulatory authorities, and a specialist physician-scientist practicing in university hospitals in Australia and the UK. As a researcher at Cambridge University, Mark pioneered the use of reverse genetics to identify novel vaccine targets as well as conducting amongst the earliest in vivo studies using nucleic acid as a novel vaccine platform. Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development. He is a fellow of the Royal College of Pathologists of Australasia (FRCPA), an affiliate physician with the Faculty of Pharmaceutical Medicine in the Royal College of Physicians, UK, and an advisor to the Commonwealth Scholarship Commission. Mark holds a Doctor of Medicine from University of Newcastle, Australia and a PhD from the University of Cambridge.
“Mark brings an extraordinary breadth and depth of experience in drug development to InterAx at a time when we are preparing to advance our pipeline to clinical trials”, noted Dr. Prior, InterAx CEO. “Mark’s scope of experience extends from early preclinical and translational medicine studies to support first-in-human trials all way to approval and the commercial process,” Dr. Prior added.
“I am very attracted to the InterAx drug discovery platform that deciphers the intracellular language that drives biological responses and applying this understanding to create truly novel therapies,” commented Dr. Levick. “I believe InterAx represents the future of drug development and with the aid of AI integrated into biological, biochemical and pharmacological data, this approach promises to reduce conventional timelines for drug development by years,” Dr. Levick added.
Dr. Rizk, InterAx CSO, added, “Dr. Levick brings a tremendous dimension of experience as we discover and develop small, orally-administered molecules with dual functions for treating diseases in a highly novel manner, starting with our cancer and inflammation programs. We are eager to work with Dr. Levick on our development plans, especially given his knowledge of the use of biomarkers as predictors of halting progression of disease.”
InterAx Biotech AG
The company, a spin-out from ETH Zurich and the Paul Scherrer Institute in Switzerland, developed an integrated drug discovery process combining biochemical compound screening, cell pathways mathematical modeling, and artificial intelligence based chemical structure to function relationship. This unique approach enables the rapid and precise identification of novel cellular mechanisms to develop differentiated products that stand out for their effectiveness and safety profiles. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks.
The company is specialized in G Protein-Coupled Receptor (GPCR) drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan GPCRs. InterAx has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry. The company is currently funded by lead institutional investors and a grant from the EU commission and is preparing for the next round of financing to grow its capabilities and advance lead drug candidates.
For more information, please visit linkedin.com/company/interax-biotech | www.interaxbiotech.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231003682932/en/
Contact information
Media: Luca Zenone, contact@interaxbiotech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC and DNV Imatis Extend Partnership to Modernize Backend Architecture and Scale e-health Solution Across Europe28.5.2025 09:13:00 EEST | Press release
HTEC, a global AI-first tech company driving digital transformation across industries, today announced the extension of its partnership with DNV Imatis, a Norwegian pioneer in digital hospital logistics and a DNV Group company. HTEC is working on modernizing the DNV Imatis platform, with the focus on backend architecture to improve scalability, strengthen security, and help the company unlock new opportunities in key European markets. The contract extension also introduces new AI initiatives that will enable two companies to explore product enhancements through AI-powered solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527604996/en/ HTEC and DNV Imatis extend partnership to modernize backend architecture and scale e-health solution across Europe DNV Imatis utilize HTEC’s expertise in system architecture to guide critical backend improvements and deliver modernization for a large and complex platform composed of
MAG GROUP and Citic Limited Sign MoU for USD 6 Billion "Keturah Ardh" Development in Dubai28.5.2025 08:40:00 EEST | Press release
In a landmark move poised to significantly shape Dubai's luxury real estate landscape, MAG Group and CITIC Limited, one of China's largest state-owned conglomerates, have announced the signing of a Memorandum of Understanding (MoU) for the development of Keturah Ardh — a visionary USD 6 billion project spanning 18.47 million square feet in the Al Rowaiyah First District of Dubai. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527056617/en/ Moafaq A. Al Gaddah, Founder and Chairman of MAG Group Holding and Yang Jianqiang, Chairman of CITIC Limited. (Photo: AETOSWire) The signing ceremony brought together two financial powerhouses: MAG Group Holding, with a portfolio valued at USD 3 billion, ongoing sales worth USD 5 billion, and developments estimated at approximately USD 17 billion; and CITIC Limited, which manages total assets exceeding USD 1.67 trillion. This collaboration marks CITIC Limited's first major entry into Du
Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering28.5.2025 08:13:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 2.38 million shares at a price of CHF 97.75 per share for a total consideration of CHF 232.5 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority and Auba Investment Pte. Ltd. launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. The repurchase, which is expected to settle on June 2, is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employee participation plans, business development opportunities and/or treasury management. “The repurchase of shares announced today is a testament to the confidence of the Executive Committee and
FES Super Extends Partnership with SS&C28.5.2025 01:13:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region. FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund. “Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver
Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 22:48:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom